Oxford BioMedica PLC (LSE:OXB) - Share price - Overview

Stock Report

Oxford BioMedica PLC OXB

Last Price
GBX8.82

Day Change
-0.10|-1.12%

As of 17/08/2017
17:46:41 BST | GBX
Minimum 15 Minutes Delay.

Last Close8.92p
Day Range8.64 - 9.22
Mkt Cap275.50Mil
52-Wk Range2.98 - 11.50
Yield %0.00
ISINGB0006648157
Volume6,494,167
P/E-14.77
P/S8.82
P/CF-48.46

Share Price

Total Returns 17/08/2017

 Chg (%)  
More ...
Oxford BioMedica PLC17.60 
FTSE 100 TR GBP1.43
 
Financials
201420152016
More ...
Income Statement
Turnover13.6215.9127.78
Operating Profit-10.61-14.08-11.31
Net Profit-8.66-13.02-16.64
Reported EPS-0.43-0.51-0.60
Balance Sheet
Current Assets22.7625.7127.44
Non Current Assets11.0526.1429.50
Total Assets33.8151.8556.94
Current Liabilities9.2313.179.32
Total Liabilities10.7740.9644.33
Total Equity23.0410.8912.62
Cash Flow
Operating Cash Flow-7.43-14.87-5.93
Net Change in Cash12.03-4.845.98
Broker Forecasts
Year EndingPre-taxEPSEPSgP/EPEGDPSYld %
More ...
'Broker Forecasts' provides consensus figures based on several brokers' views
2017-5.51-0.04--212.38---
2018-0.180.15-59.47---
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
24/07/2017PurchaseDr. Lorenzo Tallarigo8.2032,1722,638.00
17/07/2017PurchasePeter Nolan8.01249,68720,000.00
13/07/2017Exercise of OptionTim Watts0.001,325,0350.00
13/07/2017SaleMr. Martin Diggle10.03658,89966,088.00

Company Profile

Oxford BioMedica PLC is a biopharmaceutical company based in the United Kingdom. It develops gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders.

Sector

Biotechnology

Market Position

619 of 1845 Companies

Index

FTSE Small Cap ,FTSE All Share ,FTSE techMARK Focus ,FTSE techMARK All Share

Outlook

(27/04/2017) ch - "I look forward to 2017 with confidence that it will be a successful and important year for the Group"

Next Event 17/08/2017

Next interim announcement
Ratios
CompSecMkt
More ...
PER (E)115.2313.7616.76
Div Yld (E)0.004.014.16
PEG (E)0.000.621.08
ROCE-33.07182.7510.63
Op Mrgn-55.24-5.963.95
EPS Grwth0.0028.9723.34
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00

Broker Sentiment

Strong Buy0
Buy0
Hold1
Sell0
Strong Sell0
  • Strong Sell
  • Strong Buy
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
More ...
Disclaimer
Directors
More ...
ChairmanDr. Lorenzo Tallarigo
Chief Executive OfficerJohn Dawson
Chief Financial Officer & Co SecTim Watts
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2017 Morningstar. All rights reserved.